Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Solid Biosciences Inc SLDB

Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company’s lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It also develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial; SGT-501 for the treatment of catecholaminergic polymorphic ventricular... see more

Current News (NDAQ:SLDB)

Solid Biosciences to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

GlobeNewswire 1 day ago

Solid Biosciences Provides 2026 Outlook Underscoring Neuromuscular and Cardiac Pipeline Momentum and Expanded Access to Next-Generation Capsid AAV-SLB101

GlobeNewswire January 13, 2026

Solid Biosciences Receives FDA Orphan Drug Designation for SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich's Ataxia

GlobeNewswire January 12, 2026

Solid Biosciences Doses First Participant in First-in-Class Phase 1b FALCON Trial Evaluating SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich's Ataxia

GlobeNewswire January 12, 2026

Solid Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 6, 2026

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire January 5, 2026

Solid Biosciences Announces Duchenne Muscular Dystrophy Added to National Recommended Uniform Screening Panel by the U.S. Department of Health and Human Services

GlobeNewswire December 16, 2025

Solid Biosciences to Showcase Proprietary Next-Generation Capsid AAV-SLB101 and Cardiac Gene Therapy Pipeline at the 22nd Global CardioVascular Clinical Trialists (CVCT) Forum

GlobeNewswire December 8, 2025

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire December 1, 2025

Opinion & Analysis (NDAQ:SLDB)

No current opinion is available.

Bullboard Posts (NDAQ:SLDB)

Buy buddy buy because it's taking off this morning.

So that you guys will be left behind by this stock already.
coolfooldumbguy - February 18, 2025

Using technical analysis for this one.

After making a head and shoulders formation,this stock is signalling a positive uptrend for this morning.So that you guys out there...
coolfooldumbguy - February 10, 2025

Solid Biosciences Inc. (NASDAQ:SLDB): Advancing a Diverse Pi

http://beyondspx.com/2024/08/02/solid-biosciences-inc-nasdaqsldb-advancing-a-diverse-pipeline-of-gene-therapy-candidates-for-rare...
MikeTester - August 3, 2024

Crazy week

Anybody out there on this wild ride?
blazingsaddles - June 21, 2018

Podcasts